Login to Your Account



Aiming to one-up Gilead in blood cancer, Chi-Med kicks off phase I trials for PI3K delta blocker

By Shannon Ellis
Staff Writer

Monday, April 18, 2016

SHANGHAI – Hutchison China Meditech Ltd. has begun human trials for HMPL-689, a PI3K delta blocker for the potential treatment of blood cancers that it hopes can be best in class by overcoming a rival's safety issues.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription